Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5834MR)

This product GTTS-WQ5834MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5834MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14507MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ4284MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ2776MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ969MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ5876MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ9347MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ10626MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ579MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 62-71-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW